Chemotherapy in advanced prostate cancer

被引：0
作者：
Beedassy, A [1 ]
Cardi, G [1 ]
机构：
[1] Med Coll Penn & Hahnemann Univ, Ctr Canc, Div Hematol Oncol, Philadelphia, PA 19102 USA
来源：
SEMINARS IN ONCOLOGY | 1999年 / 26卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428 / 438
页数：11
相关论文
共 52 条
[31]  
RAHMAN A, 1984, SEMIN ONCOL, V11, P45
[32]   DEVELOPMENT AND VALIDATION OF A PHARMACOKINETICALLY BASED FIXED DOSING SCHEME FOR SURAMIN [J].
REYNO, LM ;
EGORIN, MJ ;
EISENBERGER, MA ;
SINIBALDI, VJ ;
ZUHOWSKI, EG ;
SRIDHARA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2187-2195
[33]  
ROSEN PR, 1996, J CLIN ONCOL, V16, P1626
[34]  
ROTH BJ, 1993, CANCER, V72, P2457, DOI 10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO
[35]  
2-Z
[36]   PHASE-II TRIAL OF DOXORUBICIN IN BIDIMENSIONALLY MEASURABLE PROSTATIC ADENOCARCINOMA [J].
SCHER, H ;
YAGODA, A ;
WATSON, RC ;
SERBER, M ;
WHITMORE, W .
JOURNAL OF UROLOGY, 1984, 131 (06) :1099-1102
[37]   FLUTAMIDE WITHDRAWAL SYNDROME - ITS IMPACT ON CLINICAL-TRIALS IN HORMONE-REFRACTORY PROSTATE-CANCER [J].
SCHER, HI ;
KELLY, WK .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1566-1572
[38]   TRIMETREXATE IN PROSTATIC-CANCER - PRELIMINARY-OBSERVATIONS ON THE USE OF PROSTATE-SPECIFIC ANTIGEN AND ACID-PHOSPHATASE AS A MARKER IN MEASURABLE HORMONE-REFRACTORY DISEASE [J].
SCHER, HI ;
CURLEY, T ;
GELLER, N ;
ENGSTROM, C ;
DERSHAW, DD ;
LIN, SY ;
FITZPATRICK, K ;
NISSELBAUM, J ;
SCHWARTZ, M ;
BEZIRDJIAN, L ;
EISENBERGER, M .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) :1830-1838
[39]   ESTRAMUSTINE AND VINBLASTINE - USE OF PROSTATE SPECIFIC ANTIGEN AS A CLINICAL-TRIAL END-POINT FOR HORMONE REFRACTORY PROSTATIC-CANCER [J].
SEIDMAN, AD ;
SCHER, HI ;
PETRYLAK, D ;
DERSHAW, DD ;
CURLEY, T .
JOURNAL OF UROLOGY, 1992, 147 (03) :931-934
[40]   PHASE-II STUDY OF KETOCONAZOLE COMBINED WITH WEEKLY DOXORUBICIN IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER [J].
SELLA, A ;
KILBOURN, R ;
AMATO, R ;
BUI, C ;
ZUKIWSKI, AA ;
ELLERHORST, J ;
LOGOTHETIS, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :683-688
123456